Subscribe To

Price Alert Latest News Economic Calendar News

NKTX / Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data from the engineered CAR NK cell therapy candidate targeting the NKG2D ligand is expected in 1H of 2022, against the end of 2021 expected earlier. Read More

Demo Live Account See Partner Details

Content Topics

Nkarta

Expects

Initial

Data

From

Cell

Therapy

Blood

Cancer

Stock

NKTX

Posted: Oct 8 2021, 08:11

Author Name: Benzinga

NKTX News

By Zacks Investment Research
October 18, 2023

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis

By GlobeNewsWire
August 3, 2023

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural

By Zacks Investment Research
June 28, 2023

Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks

Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement amo

By The Motley Fool
June 27, 2023

Why Shares of Nkarta Are Slumping Tuesday

Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company execu

By GlobeNewsWire
June 26, 2023

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural

By GlobeNewsWire
April 12, 2023

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural

By InvestorPlace
April 11, 2023

3 Biotech Stocks to Watch for Potential Breakthroughs

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory pro

By Seeking Alpha
March 26, 2023

Nkarta: Going Down Despite Solid Data Due To Fate's Debacle

NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.